Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Gains from Investment Securities (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Gains from Investment Securities for 10 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities rose 5289.99% year-over-year to $2.4 million, compared with a TTM value of $2.4 million through Sep 2025, up 5289.99%, and an annual FY2024 reading of $2.8 million, down 1.77% over the prior year.
  • Gains from Investment Securities was $2.4 million for Q3 2025 at Spero Therapeutics, down from $2.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.9 million in Q4 2021 and bottomed at $43156.0 in Q2 2024.
  • Average Gains from Investment Securities over 5 years is $2.2 million, with a median of $2.5 million recorded in 2025.
  • The sharpest move saw Gains from Investment Securities skyrocketed 12034.98% in 2021, then plummeted 99.0% in 2023.
  • Year by year, Gains from Investment Securities stood at $4.9 million in 2021, then tumbled by 97.14% to $140000.0 in 2022, then soared by 1946.85% to $2.9 million in 2023, then dropped by 1.77% to $2.8 million in 2024, then dropped by 14.72% to $2.4 million in 2025.
  • Business Quant data shows Gains from Investment Securities for SPRO at $2.4 million in Q3 2025, $2.6 million in Q2 2025, and $170271.0 in Q1 2025.